查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1677035

抗菌胜肽市場按來源、結構、作用機制和應用分類 - 2025 年至 2030 年全球預測

Antimicrobial Peptides Market by Source, Structure, Mechanism of Action, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

抗菌肽市場預計在 2024 年價值 10.5 億美元，2025 年價值 11.5 億美元，到 2030 年預計將達到 19 億美元，複合年成長率為 10.44%。

主要市場統計數據
基準年 2024 年 10.5億美元
預計 2025 年 11.5億美元
預測年份 2030 19億美元
複合年成長率（%） 10.44％

抗菌肽已成為一類強大的生物分子，能夠解決現代醫學中一些最迫切的挑戰。隨著抗生素抗藥性的增加和致病威脅的不斷演變，抗菌肽不僅因其固有的抗菌特性而且因其在各個行業中的廣泛應用而受到廣泛關注。全球科學界和市場相關人員已表現出顯著的轉變，開始探索天然和合成來源，從而推動了技術創新和治療突破。目前的天然分離化合物和合成類似物的混合格局是由嚴格的研究、強力的臨床研究和策略性投資所支撐的。

本介紹對抗菌肽市場進行了深入檢驗，並強調了抗菌肽在轉變治療模式中將發揮的關鍵作用。它邀請決策者和專家深入研究市場動態、市場區隔趨勢和市場發展的分析廣度。隨著新的臨床資料和技術進步的融合，適應性策略和前瞻性領導將決定這些有前景的分子轉化為有效治療方案的速度。

改變抗菌肽市場

近年來，在技術突破、法律規範不斷發展和消費者需求動態的推動下，抗菌肽市場經歷了變革性變化。胜肽合成和分子工程的進步使研究人員能夠提高這些分子的效力、穩定性和特異性。特別是，創新的製造技術和數位模擬工具使得胜肽序列的快速原型設計和最佳化成為可能。這些突破不僅加快了從發現到上市的時間，而且拓寬了其應用範圍。

隨著對對照臨床試驗和全面安全評估的重視程度不斷提高，情況正在改變。世界各地的監管機構正在逐步簡化核准流程，同時確保滿足嚴格的安全標準。此外，對個人化醫療和標靶治療的重新關注正在鼓勵產業相關人員投資下一代研究平台。這種持續的演變為生物技術公司、學術機構和臨床醫生之間的策略合作奠定了基礎。多學科專業知識的結合對於克服與胜肽藥物相關的傳統挑戰、實現更快的市場滲透和提高治療效果具有關鍵作用。

推動市場策略的關鍵細分洞察

詳細的細分分析顯示，抗菌肽市場由一系列細微的分類定義，每種分類都有助於全面了解該行業。細分來說，首先從胜肽的來源開始，分成天然胜肽和合成胜肽。來自動物、微生物和植物來源的天然胜肽代表了具有內在生物活性的多樣化化合物庫，而合成胜肽可以進行精確的修改以提高功效和安全性。

另一個重要的細分是基於這些化合物的結構組成。 α-螺旋肽因其有效靶向細胞膜的能力而受到認可，其BETA-片層結構在生物環境中提供穩定性和彈性，其環狀結構提供獨特的動態特性，對於客製化治療應用具有吸引力。除了結構分類之外，重點的是作用機制。有些胜肽透過細胞內標靶化發揮作用並直接影響細胞過程，而有些胜肽則利用膜孔形成來破壞致病細胞的完整性。

最後，從應用的角度來看，市場正在向農業、化妝品和食品工業等領域擴展，其中製藥業佔有顯著地位。抗菌藥物可對抗抗藥性感染，抗癌胜肽為標靶治療提供了新方法，抗真菌和抗病毒胜肽可應對新出現的微生物威脅，免疫調節劑和創傷治療配方為患者康復提供重要支持。這種多層次的細分框架使相關人員能夠利用詳細的見解，協調產品開發策略並有效分配資源。

目錄

第 1 章 簡介

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 抗生素抗藥性不斷上升推動對替代抗菌肽的需求
      • 肽合成的進展提高了抗菌肽的穩定性和功效
      • 加大研發投入，推動抗菌胜肽新型應用開發
    • 限制因素
      • 高生產成本和擴大規模的挑戰限制了抗菌肽的廣泛應用
    • 機會
      • 新興市場醫療基礎設施不斷擴大推動抗菌肽需求
      • 消費者對個人護理和農業領域永續抗菌產品的需求不斷增加
    • 任務
      • 全球監管障礙使抗菌肽的市場進入和商業化變得複雜
  • 市場區隔分析
    • 來源：天然抗菌肽對抗感染疾病和支持防禦機制的重要性
    • 用途：抗菌肽在治療感染疾病、癌症和促進創傷治療的藥用應用
  • 波特五力分析
  • PESTEL 分析
    • 政治的
    • 經濟
    • 社會
    • 技術的
    • 合法的
    • 環境

第6章 抗菌肽市場（依來源）

  • 自然的
    • 動物
    • 微生物
    • 植物
  • 合成

第7章 抗菌肽市場結構

  • 阿爾法螺旋
  • Beta 表
  • 環形

8. 抗菌肽市場（依作用機制分類）

  • 細胞內標靶化
  • 孔隙形成

第9章 抗菌肽市場（依應用）

  • 農業
  • 化妝品
  • 食物
  • 藥品
    • 抗菌
    • 抗癌藥物
    • 抗真菌
    • 抗病毒藥物
    • 免疫調節
    • 傷口癒合

第 10 章美洲抗生素胜肽市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第 11 章亞太地區抗菌胜肽市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

12. 歐洲、中東和非洲抗菌肽市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章 競爭格局

  • 2024 年市場佔有率分析
  • FPNV 定位矩陣，2024 年
  • 競爭情境分析
  • 戰略分析與建議

公司列表

  • AbbVie Inc.
  • Alexion Pharmaceuticals, Inc.
  • Amferia AB
  • AnaSpec Inc.
  • AstraZeneca plc
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Celdara Medical, LLC
  • Eli Lilly and Company
  • EnBiotix Inc.
  • Hello Bio
  • Ingenza Limited
  • Johnson & Johnson Services, Inc.
  • Magainin Pharmaceuticals, Inc.
  • Matrubials Inc.
  • MaxWell Biosciences
  • Meddenovo Drug Design
  • Melinta Therapeutics
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk A/S
  • Nuritas Ltd.
  • Peptilogics
  • Pfizer Inc.
  • Toagosei Co Ltd
  • Vertex Pharmaceuticals Incorporated
Product Code: MRR-0E33FCE5BD4D

The Antimicrobial Peptides Market was valued at USD 1.05 billion in 2024 and is projected to grow to USD 1.15 billion in 2025, with a CAGR of 10.44%, reaching USD 1.90 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 1.05 billion
Estimated Year [2025] USD 1.15 billion
Forecast Year [2030] USD 1.90 billion
CAGR (%) 10.44%

Antimicrobial peptides have emerged as a powerful class of biomolecules with the capacity to address some of the most pressing challenges in modern medicine. In the wake of escalating antibiotic resistance and evolving pathogenic threats, these peptides are garnering significant attention not only for their intrinsic antimicrobial properties but also for their versatile applications in various industries. The global scientific community and market stakeholders have witnessed a notable shift towards exploring both natural and synthetic sources, spurring innovation and therapeutic breakthroughs. With a blend of naturally isolated compounds and engineered analogs, the current landscape is underpinned by rigorous research, robust clinical studies, and strategic investments.

This introduction sets the stage for a detailed examination of the antimicrobial peptides market, emphasizing the crucial role these agents play in revolutionizing treatment paradigms. It invites decision-makers and experts to delve into the analytical expanse of market dynamics, segmentation trends, and regional developments. As emerging clinical data and technology advances converge, the stage is set for a transformative era in which adaptive strategies and forward-thinking leadership will determine the pace at which these promising molecules are translated into effective therapeutic solutions.

Transformative Shifts in the Antimicrobial Peptides Market Landscape

Recent years have witnessed transformative shifts in the antimicrobial peptides market, driven by technological breakthroughs, evolving regulatory frameworks, and dynamic consumer demands. Advancements in peptide synthesis and molecular engineering have enabled researchers to enhance the potency, stability, and specificity of these molecules. In particular, innovative manufacturing techniques and digital simulation tools now facilitate rapid prototyping and optimization of peptide sequences. Such breakthroughs are not only accelerating the timeline from discovery to market but are also broadening the spectrum of applications.

The landscape has shifted as well due to an increased emphasis on controlled clinical trials and comprehensive safety evaluations. Global regulatory bodies are progressively streamlining approval processes while ensuring that robust safety standards are met. Moreover, a renewed focus on personalized medicine and targeted therapies has galvanized industry players to invest in next-generation research platforms. This ongoing evolution is setting a foundation where strategic collaborations between biotech firms, academic institutions, and clinical practitioners are becoming pivotal. The convergence of interdisciplinary expertise is proving instrumental in overcoming traditional challenges associated with peptide-based drugs, thus enabling faster market penetration and heightened therapeutic efficacy.

Key Segmentation Insights Driving Market Strategies

In-depth segmentation analysis reveals that the market for antimicrobial peptides is defined by a series of nuanced classifications, each contributing to a holistic understanding of the industry. The segmentation begins with the source of these peptides, which is divided into natural and synthetic. Natural peptides, derived from animal, microbial, and plant origins, offer a diverse repository of compounds with intrinsic biological activity, while synthetic peptides allow for precise modifications designed to enhance efficacy and safety.

Another crucial segmentation is based on the structural makeup of these compounds. Alpha-helical peptides are recognized for their ability to target cell membranes efficiently, beta-sheet conformations offer stability and resilience in biological environments, and loop structures provide unique dynamic properties that are attractive for bespoke therapeutic applications. Beyond structural classifications, a critical dimension is the mechanism of action. Certain peptides exert their effects through intracellular targeting, influencing cellular processes directly, whereas others employ membrane pore formation to disrupt the integrity of pathogenic cells.

Lastly, when viewed through the prism of application, the market extends its reach across sectors such as agriculture, cosmetics, and food industries, with a significantly robust presence in pharmaceuticals. Within the pharmaceutical subset, the focus is multifaceted: antibacterial agents combat resistant infections, anticancer peptides offer novel approaches for targeted therapy, antifungal and antiviral peptides address emergent microbial threats, while immunomodulatory agents and wound healing formulations contribute to critical support in patient recovery. This layered segmentation framework enables stakeholders to harness detailed insights, tailor their product development strategies, and allocate resources efficiently, thereby driving market growth and innovation.

Based on Source, market is studied across Natural and Synthetic. The Natural is further studied across Animal, Microbial, and Plant.

Based on Structure, market is studied across Alpha-helical, Beta-sheet, and Loop.

Based on Mechanism of Action, market is studied across Intracellular Targeting and Membrane Pore Formation.

Based on Application, market is studied across Agriculture, Cosmetics, Food, and Pharmaceuticals. The Pharmaceuticals is further studied across Antibacterial, Anticancer, Antifungal, Antiviral, Immunomodulation, and Wound healing.

Global Regional Perspectives on Antimicrobial Peptides

A critical examination of the antimicrobial peptides market from a regional perspective reveals distinct trends that vary by geography. The Americas continue to play a dominant role, with research institutions and pharmaceutical companies fuelling progress through cutting-edge clinical studies and a supportive regulatory climate. This region's robust infrastructure and investment in biotechnology underpin dynamic advancements, ensuring that innovative therapies reach the market faster.

In Europe, Middle East & Africa, the emphasis is on blending deep-rooted scientific expertise with emergent innovation hubs. The region benefits from a mosaic of research excellence, diverse clinical trials, and strategic public-private partnerships. European markets, in particular, showcase strong collaborations in the field of healthcare, while the Middle East and Africa are rapidly emerging as competitive landscapes due to enhanced regulatory support and investment in advanced research facilities.

The Asia-Pacific is distinguished by its accelerated industrial progress and sustained growth in the biotechnology sector. Rapid economic development, coupled with significant government investments in healthcare and life sciences, has made this region a fertile ground for the adoption of antimicrobial peptides. Here, high population densities and evolving healthcare needs are driving both public and private sector initiatives to harness the therapeutic potential of these biomolecules. Together, these regional insights offer a comprehensive view of how local market dynamics are aligning with global trends, providing a strategic guide for investors and innovators alike.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Market Leaders and Key Industry Innovators

The competitive landscape of the antimicrobial peptides market is characterized by the presence of several key companies, each contributing uniquely with extensive research expertise and technological innovations. Globally recognized pharmaceutical giants such as AbbVie Inc., Alexion Pharmaceuticals, Inc., and AstraZeneca plc have been instrumental in driving the evolution of this field. Their robust R&D initiatives and expansive clinical pipelines have significantly advanced the development of both natural and synthetic peptide therapies.

Simultaneously, companies like Amferia AB, AnaSpec Inc., Bayer AG, and Boehringer Ingelheim International GmbH have established themselves as leaders by focusing on niche segments and leveraging cutting-edge technology to enhance the performance attributes of peptide-based formulations. Established industry players, including Eli Lilly and Company, Johnson & Johnson Services, Inc., and Novartis AG, reinforce the market with their strategic investments in long-term research programs and comprehensive clinical trials.

Emerging innovators such as EnBiotix Inc. and Hello Bio are redefining the market by integrating advanced biotechnological platforms with targeted therapeutic strategies. In addition, entities like Ingenza Limited and Magainin Pharmaceuticals, Inc. have introduced novel methodologies in drug design and customization, catering to unmet medical needs. Fresh market entrants such as Meddenovo Drug Design, Melinta Therapeutics, Merck KGaA, Novo Nordisk A/S, and Nuritas Ltd. have elevated industry dynamics through strategic collaborations and innovative product applications. Other influential companies including Peptilogics, Pfizer Inc., Toagosei Co Ltd, and Vertex Pharmaceuticals Incorporated have expanded market reach by adopting diverse distribution strategies and robust marketing frameworks. This collective array of corporate expertise underlines a competitive yet collaborative environment where innovation and strategic insight continue to propel the antimicrobial peptides market forward.

The report delves into recent significant developments in the Antimicrobial Peptides Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alexion Pharmaceuticals, Inc., Amferia AB, AnaSpec Inc., AstraZeneca plc, Bayer AG, Boehringer Ingelheim International GmbH, Celdara Medical, LLC, Eli Lilly and Company, EnBiotix Inc., Hello Bio, Ingenza Limited, Johnson & Johnson Services, Inc., Magainin Pharmaceuticals, Inc., Matrubials Inc., MaxWell Biosciences, Meddenovo Drug Design, Melinta Therapeutics, Merck KGaA, Novartis AG, Novo Nordisk A/S, Nuritas Ltd., Peptilogics, Pfizer Inc., Toagosei Co Ltd, and Vertex Pharmaceuticals Incorporated. Strategic Recommendations for Capitalizing on Market Opportunities

Industry leaders should prioritize robust research and development initiatives while embracing strategic partnerships to maintain a competitive edge in the antimicrobial peptides market. It is essential to invest in technology platforms that enhance peptide synthesis and structural optimization, as these innovations can substantially improve therapeutic profiles and market applicability.

Leaders are encouraged to implement targeted clinical trial designs and forge alliances with academic institutions and biotech firms to accelerate product development. A keen focus on integrating digital analytics with market intelligence will allow companies to monitor evolving trends, adapt to regulatory changes, and respond swiftly to emerging consumer needs. Furthermore, aligning investment strategies with clear segmentation insights-spanning source, structure, mechanism of action, and application-ensures that new products are developed with precision and market relevance.

Adopting a dual approach that leverages both global market trends and localized regional dynamics will enable organizations to optimize product distribution and capitalize on demographic-specific opportunities. Comprehensive market understanding and agile operational strategies will empower industry leaders to drive sustainable growth, innovate continuously, and secure their positions in an increasingly competitive landscape.

Final Thoughts on the Future of the Antimicrobial Peptides Market

In conclusion, the antimicrobial peptides market is positioned for significant growth driven by groundbreaking scientific research and innovative therapeutic applications. The complex interplay between natural and synthetic sources, along with an intricate understanding of structural and mechanistic nuances, offers diverse opportunities across multiple sectors. A careful segmentation of the market into source, structure, mechanism, and application not only enhances clarity but also aligns strategic planning with evolving clinical needs.

The integration of regional trends further enriches the market narrative, showcasing dynamic progress in the Americas, Europe, Middle East & Africa, and Asia-Pacific. With a broad spectrum of industry giants and innovative disruptors pushing the boundaries of peptide research, the path forward is marked by strategic collaboration and sustained investment. Collectively, these factors underscore a transformative era in which antimicrobial peptides are set to redefine modern therapeutics and contribute to improved patient outcomes worldwide.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising antibiotic resistance boosting demand for antimicrobial peptides as alternatives
      • 5.1.1.2. Advancements in peptide synthesis enhancing stability and efficacy of antimicrobial peptides
      • 5.1.1.3. Increased R&D investments driving the development of novel antimicrobial peptide applications
    • 5.1.2. Restraints
      • 5.1.2.1. High production costs and scaling challenges limiting widespread adoption of antimicrobial peptides
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing healthcare infrastructure in emerging markets creating demand for antimicrobial peptides
      • 5.1.3.2. Increasing consumer demand for sustainable antimicrobial products in personal care and agriculture
    • 5.1.4. Challenges
      • 5.1.4.1. Global regulatory hurdles complicating antimicrobial peptide market entry and commercialization
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Source: Significance of natural antimicrobial peptides in combating infections and supporting defense mechanisms
    • 5.2.2. Application: Pharmaceutical applications of antimicrobial peptides in treating infections, cancer, and promoting wound healing
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Antimicrobial Peptides Market, by Source

  • 6.1. Introduction
  • 6.2. Natural
    • 6.2.1. Animal
    • 6.2.2. Microbial
    • 6.2.3. Plant
  • 6.3. Synthetic

7. Antimicrobial Peptides Market, by Structure

  • 7.1. Introduction
  • 7.2. Alpha-helical
  • 7.3. Beta-sheet
  • 7.4. Loop

8. Antimicrobial Peptides Market, by Mechanism of Action

  • 8.1. Introduction
  • 8.2. Intracellular Targeting
  • 8.3. Membrane Pore Formation

9. Antimicrobial Peptides Market, by Application

  • 9.1. Introduction
  • 9.2. Agriculture
  • 9.3. Cosmetics
  • 9.4. Food
  • 9.5. Pharmaceuticals
    • 9.5.1. Antibacterial
    • 9.5.2. Anticancer
    • 9.5.3. Antifungal
    • 9.5.4. Antiviral
    • 9.5.5. Immunomodulation
    • 9.5.6. Wound healing

10. Americas Antimicrobial Peptides Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Antimicrobial Peptides Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Antimicrobial Peptides Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2024
  • 13.2. FPNV Positioning Matrix, 2024
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Beiersdorf and Macro Biologics unite to innovate biodegradable antimicrobial peptides for skin care and healthcare solutions
    • 13.3.2. Amferia's EUR 1.2 million investment increases antimicrobial peptide technology, commercial expansion, and resistance fight
    • 13.3.3. Revolutionary dmSLAY method enhances antimicrobial peptides by improving safety and selectivity
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Alexion Pharmaceuticals, Inc.
  • 3. Amferia AB
  • 4. AnaSpec Inc.
  • 5. AstraZeneca plc
  • 6. Bayer AG
  • 7. Boehringer Ingelheim International GmbH
  • 8. Celdara Medical, LLC
  • 9. Eli Lilly and Company
  • 10. EnBiotix Inc.
  • 11. Hello Bio
  • 12. Ingenza Limited
  • 13. Johnson & Johnson Services, Inc.
  • 14. Magainin Pharmaceuticals, Inc.
  • 15. Matrubials Inc.
  • 16. MaxWell Biosciences
  • 17. Meddenovo Drug Design
  • 18. Melinta Therapeutics
  • 19. Merck KGaA
  • 20. Novartis AG
  • 21. Novo Nordisk A/S
  • 22. Nuritas Ltd.
  • 23. Peptilogics
  • 24. Pfizer Inc.
  • 25. Toagosei Co Ltd
  • 26. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

  • FIGURE 1. ANTIMICROBIAL PEPTIDES MARKET MULTI-CURRENCY
  • FIGURE 2. ANTIMICROBIAL PEPTIDES MARKET MULTI-LANGUAGE
  • FIGURE 3. ANTIMICROBIAL PEPTIDES MARKET RESEARCH PROCESS
  • FIGURE 4. ANTIMICROBIAL PEPTIDES MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS ANTIMICROBIAL PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 17. AMERICAS ANTIMICROBIAL PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 19. UNITED STATES ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANTIMICROBIAL PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC ANTIMICROBIAL PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. ANTIMICROBIAL PEPTIDES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 25. ANTIMICROBIAL PEPTIDES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANTIMICROBIAL PEPTIDES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIMICROBIAL PEPTIDES MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY ANIMAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MICROBIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PLANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SYNTHETIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY ALPHA-HELICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY BETA-SHEET, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY LOOP, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY INTRACELLULAR TARGETING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MEMBRANE PORE FORMATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY AGRICULTURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY COSMETICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY FOOD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY ANTIBACTERIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY ANTICANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY ANTIFUNGAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY ANTIVIRAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY IMMUNOMODULATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY WOUND HEALING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS ANTIMICROBIAL PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC ANTIMICROBIAL PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 78. AUSTRALIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 80. AUSTRALIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 82. AUSTRALIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 84. CHINA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 85. CHINA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 86. CHINA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 87. CHINA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 88. CHINA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. CHINA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 90. INDIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 91. INDIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 92. INDIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 93. INDIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 94. INDIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. INDIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 96. INDONESIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 97. INDONESIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 98. INDONESIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 99. INDONESIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 100. INDONESIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. INDONESIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 102. JAPAN ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 103. JAPAN ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 104. JAPAN ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 105. JAPAN ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 106. JAPAN ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. JAPAN ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 108. MALAYSIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 109. MALAYSIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 110. MALAYSIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 111. MALAYSIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 112. MALAYSIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. MALAYSIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 114. PHILIPPINES ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 116. PHILIPPINES ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 118. PHILIPPINES ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 120. SINGAPORE ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 121. SINGAPORE ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 122. SINGAPORE ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 123. SINGAPORE ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 124. SINGAPORE ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. SINGAPORE ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH KOREA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH KOREA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH KOREA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 132. TAIWAN ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 133. TAIWAN ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 134. TAIWAN ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 135. TAIWAN ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 136. TAIWAN ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. TAIWAN ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 138. THAILAND ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 139. THAILAND ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 140. THAILAND ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 141. THAILAND ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 142. THAILAND ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. THAILAND ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 144. VIETNAM ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 145. VIETNAM ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 146. VIETNAM ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 147. VIETNAM ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 148. VIETNAM ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. VIETNAM ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 157. DENMARK ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 158. DENMARK ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 159. DENMARK ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 160. DENMARK ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 161. DENMARK ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 162. DENMARK ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 163. EGYPT ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 164. EGYPT ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 165. EGYPT ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 166. EGYPT ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 167. EGYPT ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 168. EGYPT ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 169. FINLAND ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 170. FINLAND ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 171. FINLAND ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 172. FINLAND ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 173. FINLAND ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 174. FINLAND ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 175. FRANCE ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 176. FRANCE ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 177. FRANCE ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 178. FRANCE ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 179. FRANCE ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. FRANCE ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 181. GERMANY ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 182. GERMANY ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 183. GERMANY ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 184. GERMANY ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 185. GERMANY ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 186. GERMANY ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 187. ISRAEL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 188. ISRAEL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 189. ISRAEL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 190. ISRAEL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 191. ISRAEL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 192. ISRAEL ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 193. ITALY ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 194. ITALY ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 195. ITALY ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 196. ITALY ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 197. ITALY ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 198. ITALY ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 199. NETHERLANDS ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 200. NETHERLANDS ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 202. NETHERLANDS ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 204. NETHERLANDS ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 205. NIGERIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 206. NIGERIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 207. NIGERIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 208. NIGERIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 209. NIGERIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 210. NIGERIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 211. NORWAY ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 212. NORWAY ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 213. NORWAY ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 214. NORWAY ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 215. NORWAY ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 216. NORWAY ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 217. POLAND ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 218. POLAND ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 219. POLAND ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 220. POLAND ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 221. POLAND ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 222. POLAND ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 223. QATAR ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 224. QATAR ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 225. QATAR ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 226. QATAR ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 227. QATAR ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 228. QATAR ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 229. RUSSIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 230. RUSSIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 231. RUSSIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 232. RUSSIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 233. RUSSIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 234. RUSSIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 236. SAUDI ARABIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 238. SAUDI ARABIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 240. SAUDI ARABIA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH AFRICA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH AFRICA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH AFRICA ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 247. SPAIN ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 248. SPAIN ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 249. SPAIN ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 250. SPAIN ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 251. SPAIN ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 252. SPAIN ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 253. SWEDEN ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 254. SWEDEN ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 255. SWEDEN ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 256. SWEDEN ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 257. SWEDEN ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 258. SWEDEN ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 259. SWITZERLAND ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 260. SWITZERLAND ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 262. SWITZERLAND ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 264. SWITZERLAND ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 265. TURKEY ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 266. TURKEY ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 267. TURKEY ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 268. TURKEY ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 269. TURKEY ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 270. TURKEY ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM ANTIMICROBIAL PEPTIDES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED KINGDOM ANTIMICROBIAL PEPTIDES MARKET SIZE, BY NATURAL, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM ANTIMICROBIAL PEPTIDES MARKET SIZE, BY STRUCTURE, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED KINGDOM ANTIMICROBIAL PEPTIDES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM ANTIMICROBIAL PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED KINGDOM ANTIMICROBIAL PEPTIDES MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 283. ANTIMICROBIAL PEPTIDES MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 284. ANTIMICROBIAL PEPTIDES MARKET, FPNV POSITIONING MATRIX, 2024